Celgene Corp. buy matumba
Start price
22.10.11
/
50%
€24.05
Target price
28.12.11
€26.08
Performance (%)
8.41%
End price
28.12.11
€26.08
Summary
This prediction ended on 28.12.11 with a price of €26.08. With a performance of 8.41%, the BUY prediction by matumba for Celgene Corp. closed with a slight gain. matumba has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Celgene Corp. | - | - | - | - |
iShares Core DAX® | 0.383% | -1.593% | 16.084% | 14.286% |
iShares Nasdaq 100 | 1.543% | 7.530% | 38.446% | 53.091% |
iShares Nikkei 225® | 2.596% | 4.525% | 14.539% | 9.353% |
iShares S&P 500 | 0.573% | 4.229% | 30.110% | 45.397% |
Comments by matumba for this prediction
In the thread Celgene Corp. diskutieren
risikobereit?
Revlimid Präparat gegen Krebs soll 2012 ein Umsatzplus von 30% bringen (3,15MRD Dollar)
Europ. Arzneimittelagentur hat sich positiv geäußert- dies ermögl. gute Chancen
(Zielkurs erreicht)